1. Home
  2. IVVD vs NMS Comparison

IVVD vs NMS Comparison

Compare IVVD & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • NMS
  • Stock Information
  • Founded
  • IVVD 2020
  • NMS 1993
  • Country
  • IVVD United States
  • NMS United States
  • Employees
  • IVVD N/A
  • NMS N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • NMS Finance Companies
  • Sector
  • IVVD Health Care
  • NMS Finance
  • Exchange
  • IVVD Nasdaq
  • NMS Nasdaq
  • Market Cap
  • IVVD 63.4M
  • NMS 67.0M
  • IPO Year
  • IVVD 2021
  • NMS N/A
  • Fundamental
  • Price
  • IVVD $0.52
  • NMS $11.27
  • Analyst Decision
  • IVVD Strong Buy
  • NMS
  • Analyst Count
  • IVVD 3
  • NMS 0
  • Target Price
  • IVVD $3.85
  • NMS N/A
  • AVG Volume (30 Days)
  • IVVD 1.2M
  • NMS 12.0K
  • Earning Date
  • IVVD 08-14-2025
  • NMS 01-01-0001
  • Dividend Yield
  • IVVD N/A
  • NMS 4.11%
  • EPS Growth
  • IVVD N/A
  • NMS N/A
  • EPS
  • IVVD N/A
  • NMS N/A
  • Revenue
  • IVVD $46,210,000.00
  • NMS N/A
  • Revenue This Year
  • IVVD $345.16
  • NMS N/A
  • Revenue Next Year
  • IVVD $161.08
  • NMS N/A
  • P/E Ratio
  • IVVD N/A
  • NMS N/A
  • Revenue Growth
  • IVVD 1941.08
  • NMS N/A
  • 52 Week Low
  • IVVD $0.35
  • NMS $9.21
  • 52 Week High
  • IVVD $2.74
  • NMS $12.18
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 32.49
  • NMS 47.82
  • Support Level
  • IVVD $0.48
  • NMS $11.19
  • Resistance Level
  • IVVD $0.65
  • NMS $11.45
  • Average True Range (ATR)
  • IVVD 0.06
  • NMS 0.11
  • MACD
  • IVVD -0.03
  • NMS -0.01
  • Stochastic Oscillator
  • IVVD 11.35
  • NMS 32.08

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About NMS Nuveen Minnesota Quality Municipal Income Fund

Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.

Share on Social Networks: